Free Trial
NASDAQ:BFRG

Bullfrog AI 3/14/2025 Earnings Report

Bullfrog AI logo
$1.81 +0.01 (+0.56%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$1.81 0.00 (0.00%)
As of 05/2/2025 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bullfrog AI EPS Results

Actual EPS
-$0.18
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bullfrog AI Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bullfrog AI Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Bullfrog AI's next earnings date is estimated for Friday, May 9, 2025, based on past reporting schedules.

Conference Call Resources

Bullfrog AI Earnings Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
See More Bullfrog AI Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bullfrog AI? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bullfrog AI and other key companies, straight to your email.

About Bullfrog AI

Bullfrog AI (NASDAQ:BFRG), through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

View Bullfrog AI Profile

More Earnings Resources from MarketBeat